A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102
1 other identifier
interventional
N/A
1 country
1
Brief Summary
Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 28, 2002
CompletedFirst Posted
Study publicly available on registry
October 30, 2002
CompletedJune 24, 2005
July 1, 2004
October 28, 2002
June 23, 2005
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Completion T1249-102;
- Currently failing a T-20 containing regimen
You may not qualify if:
- Non-completion of T1249-102.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Trimerislead
Study Sites (1)
Trimeris
Durham, North Carolina, 27707, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
October 28, 2002
First Posted
October 30, 2002
Last Updated
June 24, 2005
Record last verified: 2004-07